Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...

One of the most lethal forms of breast cancer has long shrugged off the best drugs in the oncologist’s arsenal, leaving ...

Patients who depend on antibody drugs often spend long hours in infusion centers. These medicines are vital for treating many ...

Multiplexed, multiparameter screening assays are foundational to the drug discovery process. By collecting more information, more rapidly – whether the focus antibodies, small molecules, or phenotypic ...

Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

A newly engineered antibody can penetrate kidney cysts and interrupt the growth signals that drive polycystic kidney disease.

New antibody therapy stopped tumor growth and blocked spread in treatment-resistant triple-negative breast cancer models.

First-in-human trial of candidate from the next-generation ATTC platform —— Simultaneous China and global clinical development strategy to ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...